+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Inflammatory Therapeutics Market by Therapeutic Class, Mechanism Of Action, Route Of Administration, Distribution Channel, Indication, End User - Global Forecast to 2030- Product Image
Anti-Inflammatory Therapeutics Market by Therapeutic Class, Mechanism Of Action, Route Of Administration, Distribution Channel, Indication, End User - Global Forecast to 2030- Product Image
Sale

Anti-Inflammatory Therapeutics Market by Therapeutic Class, Mechanism Of Action, Route Of Administration, Distribution Channel, Indication, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924946
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anti-inflammatory therapeutics market is progressing through a period of significant innovation, transforming treatment strategies and healthcare delivery for chronic inflammation-related conditions. This evolution is characterized by the fusion of advanced molecular insights, emerging therapeutic modalities, and complex regulatory landscapes, offering decision-makers an actionable roadmap for investment and growth.

Market Snapshot: Anti-Inflammatory Therapeutics Growth and Trends

The Anti-Inflammatory Therapeutics Market grew from USD 103.85 billion in 2024 to USD 109.49 billion in 2025. It is expected to continue growing at a CAGR of 5.38%, reaching USD 142.29 billion by 2030. Expansion is fueled by scientific advances in biologics and small-molecule inhibitors, redefining patient care and competitive positioning. Senior leaders navigating this market encounter robust innovation cycles and shifting demand patterns across regions, presenting opportunities to realign strategies for sustained value.

Scope & Segmentation

  • Therapeutic Classes: Biologics, Corticosteroids, Disease Modifying Antirheumatic Drugs, Janus Kinase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, and Phosphodiesterase Inhibitors.
  • Mechanisms of Action: Cyclooxygenase Inhibitors, Interleukin Inhibitors, Janus Kinase Inhibitors, Phosphodiesterase Inhibitors, Tumor Necrosis Factor Inhibitors.
  • Routes of Administration: Oral, Parenteral (including intramuscular, intravenous, subcutaneous), Topical (creams, gels, ointments).
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.
  • Indications: Asthma and Pulmonary Diseases, Gout, Inflammatory Bowel Disease (Crohn’s Disease, Ulcerative Colitis), Osteoarthritis, Psoriasis, Rheumatoid Arthritis.
  • End Users: Clinics, Home Care, Hospitals, Specialty Centers.
  • Geographic Coverage: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (selected major markets), Asia-Pacific (China, India, Japan, Australia, South Korea, among others).
  • Company Analysis: Includes developments and trends from AbbVie Inc., Johnson & Johnson, Amgen Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and Sanofi S.A.

Key Takeaways for Senior Decision-Makers

  • Biologics and targeted small molecules are reshaping therapeutic pathways and offering more personalized management for autoimmune and inflammatory diseases.
  • Integration of artificial intelligence, real-world evidence, and digital health solutions is streamlining both drug discovery and patient stratification, accelerating time-to-market for novel agents.
  • Evolving pricing and reimbursement models now prioritize value-based outcomes, requiring companies to demonstrate long-term benefit and engage in outcomes-based contracting.
  • Collaborative partnerships between biotech innovators and established pharmaceutical firms are unlocking additional scale and market access, particularly in emerging geographies and niche indications.
  • Patient support services and digital adherence tools are becoming essential for competitive differentiation and improved therapeutic outcomes across care settings.
  • Intellectual property strategies now emphasize combination patents and product lifecycle management to support ongoing market exclusivity.

Tariff Impact on US Supply Chains

New US tariff structures initiated in 2025 have introduced sourcing and manufacturing challenges for anti-inflammatory agents. Manufacturers are reevaluating global supply chains to cut costs, optimize logistics, and increase resilience, while seeking strategic partnerships to minimize exposure to regulatory shifts. Engagement with policymakers is ongoing to address impacts on patient access and affordability.

Methodology & Data Sources

Insights are drawn from comprehensive primary research, including interviews with key opinion leaders, clinicians, payers, and patient advocates. Secondary research encompasses peer-reviewed journals, regulatory filings, clinical trials data, and proprietary industry databases. Findings are cross-validated using statistical analysis and expert panel reviews, ensuring a robust and current market perspective.

Why This Report Matters

  • Guides executive strategy by mapping therapeutic innovation trends, competitive moves, and regulatory risks across core market segments.
  • Provides actionable intelligence for supply chain optimization, partnership development, and regional expansion in response to evolving market forces.

Conclusion

The anti-inflammatory therapeutics sector is advancing rapidly, shaped by scientific progress, data-driven strategies, and evolving care models. Decision-makers equipped with these insights can anticipate change, optimize investments, and build sustainable growth platforms within this dynamic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-Inflammatory Therapeutics Market, by Therapeutic Class
8.1. Introduction
8.2. Biologics
8.3. Corticosteroids
8.4. Disease Modifying Antirheumatic Drugs
8.5. Janus Kinase Inhibitors
8.6. Nonsteroidal Anti-Inflammatory Drugs
8.7. Phosphodiesterase Inhibitors
9. Anti-Inflammatory Therapeutics Market, by Mechanism Of Action
9.1. Introduction
9.2. Cyclooxygenase Inhibitors
9.3. Interleukin Inhibitors
9.4. Janus Kinase Inhibitors
9.5. Phosphodiesterase Inhibitors
9.6. Tumor Necrosis Factor Inhibitors
10. Anti-Inflammatory Therapeutics Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.3. Parenteral
10.3.1. Intramuscular
10.3.2. Intravenous
10.3.3. Subcutaneous
10.4. Topical
10.4.1. Creams
10.4.2. Gels
10.4.3. Ointments
11. Anti-Inflammatory Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Anti-Inflammatory Therapeutics Market, by Indication
12.1. Introduction
12.2. Asthma And Pulmonary Diseases
12.3. Gout
12.4. Inflammatory Bowel Disease
12.4.1. Crohn’s Disease
12.4.2. Ulcerative Colitis
12.5. Osteoarthritis
12.6. Psoriasis
12.7. Rheumatoid Arthritis
13. Anti-Inflammatory Therapeutics Market, by End User
13.1. Introduction
13.2. Clinic
13.3. Home Care
13.4. Hospital
13.5. Specialty Center
14. Americas Anti-Inflammatory Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Anti-Inflammatory Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Anti-Inflammatory Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Johnson & Johnson
17.3.3. Amgen Inc.
17.3.4. Novartis AG
17.3.5. Pfizer Inc.
17.3.6. F. Hoffmann-La Roche Ltd
17.3.7. Merck & Co., Inc.
17.3.8. Bristol-Myers Squibb Company
17.3.9. Eli Lilly and Company
17.3.10. Sanofi S.A.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTI-INFLAMMATORY THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. ANTI-INFLAMMATORY THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. ANTI-INFLAMMATORY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTI-INFLAMMATORY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTI-INFLAMMATORY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTI-INFLAMMATORY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 71. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 72. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 74. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 75. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 78. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 126. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 127. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 129. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 130. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 133. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 135. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 136. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 138. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 139. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 142. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 153. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 154. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 156. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 157. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 160. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 162. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 163. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 165. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 166. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 169. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 174. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 175. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 183. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 184. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 192. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 193. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 195. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 198. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 199. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 201. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 202. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 205. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 210. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 211. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 214. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 216. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 217. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 219. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 220. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 223. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 225. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 226. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 228. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 229. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 231. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 232. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 237. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 238. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 241. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 246. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 247. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 249. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 250. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 252. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 253. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 255. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 256. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 258. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 259. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 261. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 262. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 264. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 265. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 267. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 268. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 277. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 279. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 280. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 282. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 283. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 285. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 286. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 288. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 289. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 291. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 292. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 294. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 295. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 300. SWITZERLAND ANTI-INFL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Anti-Inflammatory Therapeutics market report include:
  • AbbVie Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 109.49 Billion
Forecasted Market Value ( USD ) by 2030 $ 142.29 Billion
Compound Annual Growth Rate5.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Route Of Administration, Product Type, Distribution Channel, End User, Indication - Global Forecast to 2030 - Product Image

Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Route Of Administration, Product Type, Distribution Channel, End User, Indication - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel, Route of Administration, Drug Class, Formulation, End User - Global Forecast to 2030 - Product Image

Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel, Route of Administration, Drug Class, Formulation, End User - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Non-Steroidal Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Non-Steroidal Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Anti-Inflammatory Therapeutics - Global Strategic Business Report - Product Image

Anti-Inflammatory Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From

About the Inflammation Drug Market

The Immune Disorders Drugs market is composed of drugs used to treat a variety of conditions related to the immune system. These drugs are used to treat autoimmune diseases, allergies, and other conditions that affect the body's ability to fight off infection. Inflammation drugs are a subset of these drugs, used to reduce inflammation and swelling caused by an immune response. These drugs can be used to treat a variety of conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease. They can also be used to reduce the risk of infection in patients with weakened immune systems. Inflammation drugs are typically administered orally or intravenously, and can be taken as a single dose or as part of a longer-term treatment plan. Common side effects of these drugs include nausea, vomiting, and diarrhea. Companies in the Immune Disorders Drugs market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.